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Introduction to Psychotropics in Pregnancy
Several studies document that over three-quarters of pregnant 
women take medications in pregnancy, with one-third tak-
ing multiple drugs in pregnancy.1,2 These rates are even higher 
if prenatal vitamins and iron supplements are added in. The 
drugs that are taken span a wide range of therapeutic classes 
and disease entities.
Psychiatric diagnoses are common therapeutic prob-
lems faced by women’s health providers.3 One study of 3000 
women presenting to an obstetrics/gynecology clinic for any 
type of care found that 20% of the women screened positive 
for a psychiatric disorder.3 Mental health diagnoses in preg-
nancy are associated with higher rates of complications such 
as preterm birth, hypertensive disorder, and low–birth weight 
babies.4,5 In fact, maternal mental illness is identified as a 
leading indirect cause of maternal mortality.6 Between 14% 
and 23% of pregnant women will experience a depressive dis-
order while pregnant.7 In 2003, approximately 13% of women 
took an antidepressant at some point in pregnancy, a rate that 
has doubled since 1999.8 With the high rate of mental health 
issues in pregnancy, the importance of the baseline condition 
effects on outcomes must be balanced with informed discus-
sions about the risks and benefits of medication therapy for 
the conditions.9 With the availability and proven efficacy of a 
number of new psychotropic medications, many women have a 
greater potential for symptom reduction and remission of their 
mood disorders.10 Thus, it is crucial for women’s health pro-
viders to understand the implications of psychotropic drugs in 
pregnancy.
The objective of this review article is to summarize the 
use of psychotropic drugs in pregnancy and to highlight 
research on risk and efficacy to help inform clinicians treat-
ing women with mental health disorders including depression, 
bipolar disorder (BPD), and anxiety. The authors performed 
Ovid and PubMed searches to find relevant articles about the 
individual drugs, drug classes, and pregnancy. The data found 
are summarized below.
Pharmacology Changes in Pregnancy and General 
Considerations
Pharmacotherapy in pregnancy has unique challenges for 
providers. There are several key changes in maternal physiol-
ogy that can affect the dosing and efficacy profiles of differ-
ent drugs. Cardiovascular changes include increased cardiac 
output and blood volume expansion to allow for adequate 
perfusion of vital organs, including the placenta and develop-
ing fetus.11 In addition, maternal total body water increases 
near the end of gestation, which may cause a dilution effect on 
certain drugs.12 Plasma albumin decreases, which can impact 
protein-bound drugs. Gastric transit time is slowed in preg-
nancy and renal plasma flow and glomerular filtration rate are 
both increased.11 Thus, physiological changes that accommo-
date the developing pregnancy can have profound impact on 
medications in pregnancy, potentially necessitating a higher 
dose of medication than would be commonly utilized for 
nonpregnant populations.13,14 In addition, as each trimester 
passes, not only does the maternal physiology change but also 
the risks of taking medications change. In the first trimester, 
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concern about teratogenicity and major fetal anomalies during 
the initial development of fetal organs and systems is present. 
Second and third trimester risks are focused on fetal growth 
and development of adverse pregnancy outcomes such as pre-
term birth or stillbirth.
These pregnancy changes and need to take medications 
are also balanced with the fear of teratogenic risk of medi-
cations. In general, teratogenic risk is overestimated by both 
patients and medical specialty providers.15 Teratogenic risks 
for some classes like antidepressants are small.16 However, 
there are thousands of calls from concerned women and pro-
viders to teratology services such as Motherrisk in Canada 
(www.motherrisk.org) and MotherSafe in Australia (www.
mothersafe.org.au) each year.17 The number of calls to these 
services continues to rise. The most common class of medica-
tions after over-the-counter drugs is for psychotropic medica-
tions, typically antidepressants.17 To address the maternal and 
neonatal risks of both depression and antidepressant exposure 
algorithms to help guide providers and patients, the American 
Psychiatric Association and American College of Obstetri-
cians and Gynecologists released a consensus report several 
years ago.18,19 The remainder of this article will describe dif-
ferent psychotropic medications used in pregnancy, the clini-
cal need for the medications, and the risks associated with 
them. This will be accomplished for several mental health 
conditions, including depression, BPD, and anxiety.
Antidepressants
selective serotonin reuptake inhibitors. Selective sero-
tonin reuptake inhibitors (SSRIs) are a class of medications 
indicated for the treatment of depression and anxiety. SSRIs 
are the most commonly prescribed treatment for depression 
both outside of pregnancy and during pregnancy.18,20,21 United 
States prevalence rates of SSRI use in pregnancy range from 
8% to 13%.8,20 Since up to 50% of pregnancies are unplanned, 
it is important for patients and health-care providers to be 
familiar with the impact of fetal exposure to SSRIs when 
prescribing these medications to women of reproductive age. 
While SSRIs are the mainstay of therapy and generally con-
sidered to be safe for use in pregnancy, there are some risks 
that must be considered. Areas of concern regarding in utero 
exposure to SSRIs include cardiac, pulmonary, and central 
nervous system.
In 2005, the Food and Drug Administration (FDA) 
reclassified paroxetine to category D due to concerns for 
increased risks for congenital heart malformations, specifically 
right ventricular outflow tract obstruction.20 At the same time, 
sertraline, while not reclassified, had also been associated with 
an increased risk for ventricular septal defects.20 A follow-up 
nationwide cohort study of 949,504 pregnant Medicaid recipi-
ents from 2000 to 2007 showed a relative risk of any cardiac 
defect of 1.25 (95% confidence interval [CI], 1.13–1.38) in 
an unadjusted analysis of women using an SSRI in the first 
trimester. However, when adjusted for patients with only a 
depression diagnosis to control for confounding comorbid 
conditions, the relative risk was 1.12 (95% CI, 1.00–1.26). 
Additionally, a third fully adjusted analysis applied a propen-
sity-score stratification to further control for depression sever-
ity and other potential cofounders, which revealed a relative 
risk of 1.06 (95% CI, 0.92–1.22). The study also analyzed cat-
egories of cardiac defects including right ventricular outflow 
tract obstruction, ventricular septal defects, and any cardiac 
malformation. Contrary to previous evidence, they found no 
significantly increased risk for paroxetine and right ventricu-
lar outflow tract obstruction and for ventricular septal defects 
with sertraline.20
A Danish cohort study examining 72,280 pregnancies 
using the EUROCAT register (database of congenital anom-
alies) from 1995 to 2008 showed an increased risk of severe 
congenital heart defects (CHD) with first-trimester SSRI 
exposure. Twelve percent of pregnant women filled an SSRI 
prescription in the first trimester, with citalopram being the 
most commonly redeemed (35.4%). Of the 845 exposed, 11 
CHD were noted, with 6 categorized as severe. The odds ratio 
for all CHD was 1.75 (95% CI, 0.96–3.19) and that for severe 
CHD being 4.15 (95% CI, 1.82–9.44). Data on maternal age, 
smoking, and exposure to antiepileptic drugs and insulin were 
collected; however, due to the limitations of the EUROCAT 
register, data were not collected on additional cofounders. 
Interestingly, this study confirmed information from a previous 
Danish study that showed an increased risk of CHD in patients 
who were exposed to SSRIs 3–12 months prior to pregnancy 
but not exposed during pregnancy. Overall, the study showed 
a low incidence of all CHDs (1.3%) in exposed pregnancies but 
did show a four-fold increased risk for severe CHD (Adjusted 
Odds Ratio [AOR] 4.03 [95% CI, 1.75–9.26]).21
Persistent pulmonary hypertension of the newborn is a 
rare condition with a prevalence of 1.9 per 1000 live births.22 
During the immediate transition following birth, the neonatal 
lungs inflate and lung blood vessels relax, leading to proper 
neonatal oxygenation. Persistent pulmonary hypertension 
does not permit pulmonary vessel relaxation, resulting in poor 
oxygenation and subsequent respiratory distress.22 The degree 
of persistent pulmonary hypertension can range from mild 
to severe hypoxia. Previous studies regarding fetal exposure 
to SSRIs have yielded inconclusive results ranging from no 
association to trimester-associated risk to increased overall 
risk. In 2014, a systematic review and meta-analysis of seven 
studies reported no significantly increased risk of persis-
tent pulmonary hypertension with SSRI utilization in early 
pregnancy (OR 1.23; 95% CI, 0.58–2.60) but did report an 
increased risk for exposure in late pregnancy (OR 2.50; 95% 
CI, 1.32–4.73).22 Due to the rare nature of this condition, the 
authors used the OR to approximate the RR. With an OR 
of 2.5 and a baseline risk of 1.9/1,000 live births, the abso-
lute risk of persistent pulmonary hypertension was 2.85/1,000 
live births for late pregnancy exposure. Thus, the number 
needed to harm (NNH) was 351 women. However, the OR 
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for early pregnancy exposure was 1.23, leading to an absolute 
risk of 0.44/1,000 lives births, resulting in an NNH of 2,288 
women.22 Overall, the risk of potential neonatal risks must 
be considered in relation to maternal risk of poorly treated 
depression with attention on late trimester exposure.
Another area of concern is the effect of SSRI exposure to 
the developing fetal central nervous system. A retrospective 
cohort study of children with intrauterine exposure to SSRIs 
matched 1:2 to children without intrauterine SSRI exposure 
when considering Chiari I malformations (CMI) at 1 and/or 2 
years on MRI. The SSRI-exposed group had an increased risk 
of CMI diagnosis compared to the group with no maternal 
depression and no SSRI exposure (18% vs 2%, P = 0.003, OR 
10.32, 95% CI 2.04–02.46).23 Duration of exposure, exposure 
at conception, and family history of depression appeared to 
increase this risk. The authors conclude that is it uncertain if 
the SSRIs were the primary risk of CMI or if the severity of 
depression during pregnancy impacts the rate of CMI.
However, given that these absolute risks are small and the 
risks that untreated depression in pregnancy is also associated 
with adverse outcomes, SSRIs remain the first-line treatment 
of choice for pregnant women with depression.9,10,18,19 Titrat-
ing the dose to antidepressant effect is often necessary due to 
the physiologic changes in pregnancy noted earlier. Women 
who breast feed after delivery can also continue to be treated 
with SSRI drugs as serum drug levels in infants who were 
breastfed by antidepressant-treated mothers were undetect-
able or low and no adverse impact was observed.24
sNrIs. The main SNRIs in clinical use include venla-
faxine, desvenlafaxine, and duloxetine. While these drugs 
are used for first-line therapy, they are also utilized when 
patients have poor responses or intolerable side effects to 
SSRIs. These drugs are effective at treating depression and 
are associated with mild side effects of nausea, dizziness, and 
diaphoresis. Studies have demonstrated no increased risk 
of adverse pregnancy outcomes with venlafaxine compared 
to SSRIs and nonteratogenic drugs,25 but a recent system-
atic review found an association with venlafaxine and an 
increased risk of spontaneous miscarriage (OR 2.1, 95% CI, 
1.3–3.3).26 While SSRI-induced neonatal abstinence syn-
drome has been found with antidepressant exposure, only 3% 
of the women were taking venlafaxine, and thus, no specific 
relationship was found.27 In general, longer term follow-up 
of infants exposed to venlafaxine in utero have noted that 
these exposed infants have done well.28 These drugs cross 
the placenta and also are secreted into breast milk. How-
ever, while venlafaxine is detected in the mother’s milk with 
a mean infant dose of 3.49%, venlafaxine was not detected in 
infant plasma. In addition, there was no evidence of adverse 
effects in breastfeeding infants.24 However, the American 
Academy of Pediatrics (AAP) classifies antidepressants 
together as drugs for which the effect on nursing infants is 
unknown but may be of concern.29 Clinically, however, the 
risks must be weighed against the benefits of treating the 
new mother for depression and the benefits of breastfeeding 
for mother and baby.
tricyclic antidepressants. Tricyclic antidepressants 
(TCAs) are the major category of psychotropic medications 
compared to SSRIs for the treatment of depression. Like 
many psychotropic medications, evidence for the risk/benefit 
of TCA use in pregnancy has been mixed. A meta-analysis 
of early studies from 1966 to 1995 did not find evidence for 
an increased risk of congenital malformations in 414 patients 
exposed to TCA in the first trimester.30 A subsequent study 
comparing infants exposed to TCA (209 infants) versus SSRI 
(185 infants) did not find evidence of adverse effects in either 
group.31 Another study of 167 pregnancies exposed to TCA 
did not find conclusive evidence for a link with birth defects, 
but did link TCA exposure with respiratory distress syndrome, 
metabolic, and endocrine abnormalities in the newborn.32 
While these data appear to portray a favorable risk profile for 
the use of TCA in pregnancy, all the studies were limited by 
a small sample size. A more recent study of women in Sweden 
captured a larger number of women exposed to TCA (1,662 
pregnancies), although nearly 70% of these utilized one agent, 
clomipramine.33 This study compared a range of perinatal out-
comes between women treated with TCA and SSRI agents 
for depression and largely concluded that outcomes after TCA 
exposure were worse than those after SSRI exposure. A range 
of detrimental effects were present to a more severe degree in 
women using TCA, including preterm birth, low birth weight, 
low APGAR score, hypoglycemia, and jaundice. Finally, 
the risk for congenital cardiac malformations was judged to 
be higher with exposure to TCA than any SSRI other than 
paroxetine. While the Reis and Kallen study has provided an 
analysis of the largest cohort of patients exposed to TCA, it 
was limited by the predominant use of just one TCA (clomip-
ramine) and general applicability of the study results. Another 
concern is that it is unclear whether the subjects were ade-
quately matched for disease (depression) severity, which may 
independently affect perinatal outcomes. Further research is 
needed to reconcile the differences in perinatal risk proposed 
by the various studies of TCA use in pregnancy.
One TCA which has received increasing attention 
recently is mirtazapine, a tetracyclic antidepressant that is 
postulated to act through a variety of mechanisms. Although 
mirtazapine does not have any pregnancy-specific pharma-
cokinetic literature, it has been documented to have linear 
kinetics within the typical dose range and achieve steady 
state within 5 days. Elimination is primarily through renal 
and hepatic routes, with a longer elimination half-life noted 
in women. There are a few studies, primarily case reports or 
small case series, documenting safety and efficacy from the use 
of mirtazapine in pregnancy. Uguz has documented successful 
use of a low-dose mirtazapine regimen for the treatment of 
major depression without neonatal complications.34 Another 
case report documented delivery of healthy twin infants after 
exposure to mirtazapine in pregnancy; no abnormalities were 
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detected at birth, and the infants demonstrated normal devel-
opment at a 6-month follow-up.35 Future investigations of 
specific medications may prove to be more useful than analy-
sis of the entire class of TCA drugs in identifying promising 
therapies for women with depression during pregnancy.
TCA medications are generally excreted into breast milk 
in low quantities, often with undetectable infant plasma levels. 
The AAP classifies most TCA as drugs whose effect on nurs-
ing infant is unknown but may be of concern.29
other antidepressants. Bupropion is a unique anti-
depressant of the aminoketone class that neither inhibits 
monoamine oxidase nor alters reuptake of serotonin or nor-
epinephrine. The antidepressant activity is not fully charac-
terized and the compound is used clinically also for smoking 
cessation. The final report of the Bupropion Pregnancy Reg-
istry committee and other prospective studies found no 
increased risk of major teratogenic effects.36 Studies that have 
noted a possible increased risk of conditions such as child-
hood ADHD are potentially confounded by other factors 
such as smoking.37 The preponderance of the evidence points 
to the use of bupropion in pregnancy as low risk. Bupropion is 
excreted into breast milk but despite an elevated milk:plasma 
ratio, a review of antidepressant treatment during breastfeed-
ing found no information that bupropion exposure during 
nursing resulted in quantifiable amounts of the drug in the 
infant or any adverse effects.38
bipolar Medications
BPD is a mental illness categorized as an affective mood dis-
order and is estimated to have a lifetime prevalence of 1%–2% 
worldwide.39 Typical onset of disease occurs in a person’s early 
20s, putting many women at risk of developing the illness 
at the height of their reproductive years.40 The female gen-
der itself predisposes a woman with BPD to suffering more 
depressive versus manic episodes than her male counterparts 
and is also associated with higher incidence of sexual promis-
cuity, sexually transmitted infections, unplanned pregnancy, 
sexual assault, and other comorbidities such as tobacco and 
alcohol abuse.41 In the pregnant woman with BPD, her risk of 
postpartum psychosis can be as great as 20%–30%, compared 
with 0.2% for the nonaffected population.42
Beyond stabilization of acute symptoms, long-term 
treatment of BPD has typically involved use of psychotropic 
medications such as mood stabilizers, anticonvulsants, and 
antipsychotics, either alone or in combination. Many of these 
treatments, however, have long been associated with fetal 
congenital malformations, neurodevelopmental problems, or 
other adverse neonatal events. On the other hand, abruptly 
stopping treatment during pregnancy increases a woman’s 
risk of relapse.43 Managing BPD in pregnancy is a challeng-
ing task for any health-care provider and requires recogniz-
ing the risks and benefits associated with each medication, 
as well as that associated with removing treatment during 
pregnancy.
No medical treatment. As a risk factor for neonatal 
morbidity, having BPD alone is associated with infants born 
severely large for the gestational age, and especially among 
women previously hospitalized for the illness, there are sig-
nificantly higher risk of congenital malformations, neonatal 
morbidity, and neonatal hospital readmission.44
While some studies have shown a protective effect of 
pregnancy on the symptoms of BPD,43,45 childbirth and the 
postpartum period can be seen to increase the risk of relapse 
up to 50%.46 Untreated BPD in pregnant and postpartum 
women has been linked to an increase in the hazardous and 
impulsive behavior, already noted to be higher at baseline in 
women versus men.41 This includes a more rapid manic-to-
depression cycling course and a significant increase in suicidal 
ideations, attempts, or death; suicide may even account for 
one-fifth of total postpartum deaths.40,47 Decision to forego 
treatment of a pregnant patient with BPD must include an 
assessment of her baseline frequency and quality of episodes, 
number of prior hospitalizations, any history of postpartum 
psychosis, and there must be a well-discussed plan for any 
acute exacerbations.
Lithium. Lithium has been a first-line treatment in BPD, 
effective in both manic and depressive episodes and also in 
reducing the risk of suicidality.48 It is not without risks, how-
ever. In 1973, a major report from the International Registry 
of Lithium Babies published data suggesting that the rate of 
congenital malformations, especially that of Ebstein’s anom-
aly, was excessively increased than that of the general popula-
tion.49 Subsequent studies put the risk for Ebstein’s anomaly 
and other major congenital malformations much lower than 
previously thought with only a slight increase in the risk of 
cardiac anomalies specifically (one case per 1,000–2,000 
births).50,51
An often reported significant effect of lithium therapy 
is birth of large for gestational age (LGA) infants, with 
affected babies weighing an average of ∼100 gm heavier than 
their nonexposed counterparts.51,52 Neonatal hypotonicity or 
“floppy baby” syndrome is also a noted adverse outcome of 
neonatal lithium toxicity, often resolving completely after the 
drug clearance.9,40 There are no data that support or describe 
any detrimental long-term behavioral or developmental effects 
on neonates of mothers treated with lithium.49,51
Lithium therapy is not contraindicated during pregnancy. 
The risk of maternal instability after abrupt discontinuation 
of therapy compared with the risk of adverse fetal effects is a 
main reason to maintain lithium therapy in such patients.40 
If a woman continues Lithium therapy during conception 
and pregnancy, it is recommended that she undergo a fetal 
echocardiography in addition to her routine anatomy ultra-
sound.52 In a well-controlled BPD patient in whom expect-
ant management is appropriate, either medication tapering or 
drug discontinuation during the first trimester is a reasonable 
choice. Lithium is excreted into breast milk, and the infant 
serum levels are near therapeutic levels. For these reasons, this 
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is classified as a drug that should be used with caution in nurs-
ing mothers.29
Antiepileptic drugs (Aeds). Anticonvulsant drugs 
can be used for both the long-term and acute treatment of 
BPD. These drugs have shown a higher teratogenicity rate 
than lithium when used during pregnancy, especially when 
used in combination or at a preexisting low-folate level at the 
time of conception.53 Typical features of fetuses exposed to 
antiepileptic medications include problems with neural tube 
embryology, growth restriction, and hypoplasia of the midface 
and finger.54 These major malformations can be seen in around 
25% of children exposed to AED in utero.55 The three most 
common AEDs used for BPD are valproate (VPA), carbam-
azepine (CBZ), and lamotrigine.
Valproate. VPA or valproic acid is associated with the 
largest number of fetal and neonatal abnormalities compared 
to all other BPD treatments and can affect almost every organ 
system. The risk is dose dependent and is increased when used 
with other AEDs, especially if the patient has already delivered 
an affected child.54,56 Neural tube defects, which are typically 
lumbosacral in nature, are among its most devastating effects, 
and the risk of NTDs can reach 1%–2%.55,56 Other malfor-
mations reported are facial clefting, hypospadias, and skeletal 
abnormalities.57 Additionally, VPA has been clearly shown to 
have effects on the cognitive, verbal, behavioral, and neurode-
velopmental abilities,56,58 and the FDA released a drug-safety 
announcement regarding these findings in 2011. In general, it 
is highly recommended that women in their reproductive years 
be counseled regarding the effects of VPA on a fetus, and, 
if desiring pregnancy, should attempt to change to another 
medication for BPD control. VPA is only excreted into breast 
milk in low concentrations and is classified as compatible with 
breastfeeding.29
Carbamazepine. Overall, the use of carbamazepine has 
been more favored than the use of other antiepileptics for use 
during pregnancy. In most major studies, the overall malfor-
mation rates are lower than those compared with VPA,59,60 
with rates ranging from 2.5% to 6.6%.52,53,59,60 The most 
common malformations noted with carbamazepine use are 
neural tube defects, decreased head circumference and body 
length, and specific facies (short nose, hypertelorism, upslant-
ing palpebral fissures).61,62 In regards to neurodevelopmental 
outcomes, there has been no significant difference reported 
in the literature in infants with carbamazepine exposure to 
nonexposed children.63 While it should be used with cau-
tion, carbamazepine may be a safer overall choice than VPA 
if treatment options must include an antiepileptic drug for 
the treatment of BPD. However, caution must still be used 
due to its risk of fetal effects, and an extensive ultrasound and 
fetal echocardiography are recommended.61 Carbamazepine is 
considered compatible with breastfeeding due to low excretion 
into milk.29
Lamotrigine. Relative to its other antiepileptic counter-
parts, data on lamotrigine are limited, particularly in regard to 
its use during pregnancy. In most studies to date, it has been 
reported to be less hazardous than other AEDs.64–66 Women 
of reproductive age who use lamotrigine have been shown to 
be less likely to have an unplanned pregnancy, and, if pregnant, 
appear to have an increased protection against bipolar depres-
sion.67 Use of the drug is associated with congenital mal-
formations, with a most common rate of 2%–3% reported.67 
Slightly increased rates of facial clefting, hypospadias, and 
intestinal anomalies have been discussed; however, most of 
those rates are very near control rates.55,59 To date, there have 
been no significant studies linking lamotrigine use in preg-
nancy with the risk of adverse neonatal neurodevelopmental 
outcomes.58 Lamotrigine is present in variable quantities in 
breast milk.68 Because of this, the AAP classifies it as a drug 
for which the effect on a nursing infant is unknown but may 
be of concern.29
Antianxiety
Treatment for anxiety during pregnancy is controversial given 
the limited pharmacotherapeutic options. Most recommenda-
tions begin with early screening and treatment with nonphar-
maceutical interventions in a multidisciplinary setting first 
(exercise, psychotherapy, etc).69,70 Approximately 10%–15% 
of pregnant women will experience depression and/or anxiety 
symptoms, with a high rate of relapse with discontinuation of 
pharmacotherapy during pregnancy.71,72 Maternal depression 
and anxiety have been correlated with spontaneous preterm 
delivery, cesarean delivery, as well as long-term maternal and 
neonatal well-being.73–75
benzodiazepines. Benzodiazepines (BDZs) are the most 
commonly prescribed treatment for generalized anxiety disor-
der despite FDA Pregnancy Categories of D or X. Recent stud-
ies estimate the use of prescribed BDZ use at 4% for pregnant 
women in the United States.76,77 Early safety reports of BZD’s 
teratogenicity were overstated, but there remains conflicting 
evidence on the fetal effects and neonatal outcomes. Initial 
studies described a significant association between major mal-
formations, increased rates of spontaneous abortion, or skeletal 
anomalies. However, many studies and several meta-analyses 
have shown no evidence of these associations.74,76,78–80 There 
are data from case–control studies associating oral cleft with 
BDZ use, though this is refuted by cohort studies.76
Neonates exposed to long-term BDZ may require a taper 
to avoid poor neonatal adaptation (PND).81 This condition is 
likely related to fetal and neonatal toxicity and includes low 
birth weight, poor muscle tone, irritation, and agitation.73,81,82 
Lorazepam has been shown to have lower fetal cord blood 
concentration than other BDZs but has not been shown to 
decrease effects on the neonate.82 Breastfeeding may be pro-
tective and should be encouraged in mothers using BDZ not 
only for the passive medication administration but also to 
promote bonding between mother and infant and to prevent 
postpartum depression and anxiety, all of which present mini-
mal risk to the newborn.82
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Buspirone. Buspirone is a non-BDZ with a similar effec-
tiveness as BDZ but requires 2–3 weeks of consistent use to 
become effective. There have been no reported cases of PND 
with the use of buspirone, though maternal withdrawal can 
occur with abrupt cessation.80,81 There are limited safety data 
in pregnancy, but results thus far are promising. For breast-
feeding women, the AAP classifies essentially all anxiolyt-
ics together that there may be concern because of effects on 
the developing brain that may not be apparent until later 
in life.29 Conclusive studies, however, are lacking and thus 
individualized counseling on risks and benefits should be 
undertaken.
summary and Conclusions
There is little doubt that the identification and treatment of 
mental health disorders are a public health priority. In addi-
tion, during pregnancy where there are additional consid-
erations, this is particularly important in order to optimize 
maternal and infant outcomes. Psychotropic medications are 
often needed to treat these conditions. Because pregnancy 
studies are not abundant for various historical and ethical 
reasons,83 the information known about the impact of psy-
chotropic medications in pregnancy is not complete.9,19,84 
The development of teratology registries and “help lines” has 
helped with data gathering on medication exposure in early 
pregnancy. However, there are conflicting findings and in 
general, treatment with psychotropic drugs and other drugs 
in pregnancy is left up to a shared informed decision with the 
patient and provider.
Individualized pharmacotherapy may help in the future 
to optimize psychotropic drug therapy in pregnancy while 
minimizing the risks. Taking into account physiological 
changes in pregnancy can help clinicians arrive at an ade-
quate dose more rapidly. In addition, the advent of pharma-
cogenomics and accounting for drug metabolizing enzyme 
and transporter changes in pregnancy may aid in developing 
therapeutic models for these drugs in pregnancy.85 Many of 
the psychotropic drugs are metabolized by enzymes that are 
impacted by commonly prescribed medications in pregnancy, 
such as antacids, gastrointestinal medications, and cardio-
vascular drugs (http://medicine.iupui.edu/CLINPHARM/
ddis/main-table). Because so many pregnant women take 
multiple medications, it is important to take all these factors 
into consideration when prescribing or continuing a psycho-
tropic medication.
In conclusion, there are risks and benefits with all medi-
cations in pregnancy. Psychotropic medications are no dif-
ferent. Understanding the risks of the mental health disorder 
in pregnant woman and the developing baby are important 
considerations when making clinical decisions with patients 
about treatment options. Weighing pregnancy characteris-
tics, impact of the mental health condition, and the potential 
risks and benefits of the drug will help patients and providers 
arrive at a shared decision about therapy. The importance of 
developing good databases of psychotropic medications and 
potential effects is paramount. In addition, long-term studies 
are needed to determine the impact of both the mental health 
condition and the drug therapy on the developing infant. The 
impact of the drug on breastfeeding and the possible impact 
on breast-fed infants is another consideration for research pri-
orities. Given that many pregnant women suffer from mental 
health conditions during pregnancy, it is important for provid-
ers to understand the implications and options for treatment 
with psychotropic medications.
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